HLA-A and myelodysplastic syndrome: The patient who developed primary GF was a 63-year old female with 2 prior pregnancies, diagnosed with high risk MDS (excess blasts type 2 MDS, without myelofibrosis) without prior polytransfusion who received a myeloablative haplo-HSCT from her brother against whom she presented anti-class I DSAs against locus HLA-A*32 with 14000 MFI, and C3d fixation detected prior to desensitization therapy.